AU4307396A - Kit for osteoporosis treatment cycle - Google Patents

Kit for osteoporosis treatment cycle Download PDF

Info

Publication number
AU4307396A
AU4307396A AU43073/96A AU4307396A AU4307396A AU 4307396 A AU4307396 A AU 4307396A AU 43073/96 A AU43073/96 A AU 43073/96A AU 4307396 A AU4307396 A AU 4307396A AU 4307396 A AU4307396 A AU 4307396A
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
tiludronic acid
calcium
kit
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU43073/96A
Other languages
English (en)
Inventor
Martine Gazard
Jacques Girard
Olivier Gros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of AU4307396A publication Critical patent/AU4307396A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU43073/96A 1994-12-06 1995-12-05 Kit for osteoporosis treatment cycle Abandoned AU4307396A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9414630A FR2727629A1 (fr) 1994-12-06 1994-12-06 Trousse pour cycle de traitement de l'osteoporose
FR9414630 1994-12-06
PCT/FR1995/001596 WO1996017616A1 (fr) 1994-12-06 1995-12-05 Trousse pour cycle de traitement de l'osteoporose

Publications (1)

Publication Number Publication Date
AU4307396A true AU4307396A (en) 1996-06-26

Family

ID=9469504

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43073/96A Abandoned AU4307396A (en) 1994-12-06 1995-12-05 Kit for osteoporosis treatment cycle

Country Status (20)

Country Link
EP (1) EP0797444A1 (pt)
JP (1) JPH10509729A (pt)
KR (1) KR980700083A (pt)
CN (1) CN1168634A (pt)
AR (1) AR002946A1 (pt)
AU (1) AU4307396A (pt)
BR (1) BR9509961A (pt)
CA (1) CA2207028A1 (pt)
CZ (1) CZ175397A3 (pt)
FI (1) FI972383A0 (pt)
FR (1) FR2727629A1 (pt)
HU (1) HUT77382A (pt)
IL (1) IL116168A0 (pt)
MA (1) MA23737A1 (pt)
NO (1) NO972558L (pt)
PL (1) PL320564A1 (pt)
SK (1) SK68597A3 (pt)
TR (1) TR199501530A1 (pt)
WO (1) WO1996017616A1 (pt)
ZA (1) ZA9510184B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
CN100551377C (zh) 2002-05-10 2009-10-21 弗·哈夫曼-拉罗切有限公司 用于治疗和预防骨质疏松症的二膦酸
PL212072B1 (pl) * 2002-12-20 2012-08-31 Hoffmann La Roche Tabletka zawierająca jako substancję czynną do 250 mg kwasu ibandronowego oraz sposób jej wytwarzania

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162510B1 (en) * 1984-04-30 1991-08-28 THE PROCTER & GAMBLE COMPANY Kit for use in the treatment of osteoporosis
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
ES2111163T3 (es) * 1992-06-30 1998-03-01 Procter & Gamble Pharma Uso de fosfonatos para el tratamiento de la osteoporosis.
FR2694558B1 (fr) * 1992-08-05 1994-10-28 Sanofi Elf Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
NO972558L (no) 1997-08-05
JPH10509729A (ja) 1998-09-22
PL320564A1 (en) 1997-10-13
MA23737A1 (fr) 1996-07-01
SK68597A3 (en) 1997-11-05
MX9704105A (es) 1997-09-30
EP0797444A1 (fr) 1997-10-01
CA2207028A1 (en) 1996-06-13
AR002946A1 (es) 1998-05-27
CZ175397A3 (en) 1997-10-15
FR2727629A1 (fr) 1996-06-07
CN1168634A (zh) 1997-12-24
NO972558D0 (no) 1997-06-05
FR2727629B1 (pt) 1997-02-28
TR199501530A1 (tr) 1996-10-21
FI972383A (fi) 1997-06-05
WO1996017616A1 (fr) 1996-06-13
BR9509961A (pt) 1997-11-25
FI972383A0 (fi) 1997-06-05
HUT77382A (hu) 1998-04-28
KR980700083A (ko) 1998-03-30
ZA9510184B (en) 1996-06-11
IL116168A0 (en) 1996-01-31

Similar Documents

Publication Publication Date Title
US20050026871A1 (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
US20050214388A1 (en) Multivitamin formulations containing controlled-release magnesium
US4861590A (en) Sustained release fluoride and calcium composition
CA2454200A1 (en) Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
DE69837450T2 (de) Alendronate zur Behandlung von Osteoporose
KR100263284B1 (ko) 활성성분으로서의 디클로로메틸렌디포스폰산을 함유하는 생체 이용률이 개선된 정제
US20170157001A1 (en) Compositions Comprising Strontium and Uses Thereof in the Treatment or Prevention of Gingivitis, Periodontitis, Periodontitis as a Manifestation of Systemic Diseases, and Necrotizing Periodontal Diseases
AU607154B2 (en) Oral sustained release preparation of sodium monofluorophosphate
US5013728A (en) Composition for treating osteoporosis and hormonal imbalance
CA2671727C (en) A composition containing a bisphosphonic acid in combination with vitamin d
CZ219798A3 (cs) Prostředek pro prevenci a léčbu osteoporézy
AU4307396A (en) Kit for osteoporosis treatment cycle
EP0521057A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING IPRIFLAVONE, PROCESS FOR THE PREPARATION AND PHARMACEUTICAL USES OF THESE COMPOSITIONS.
US5286490A (en) Transdermal fluoride medication
MXPA97004105A (en) Set for use in a therapeutic treatment cycle of osteoporo
CA2219354A1 (en) Prevention of tooth loss by the administration of alendronate or its salts
HU211084B (en) Process for producing oral pharmaceutical composition of bone strengthening activity
US4517309A (en) Method for the treatment of calcifying pancreatitis
EP0268868A2 (en) Pharmaceutical compositions for the treatment of gastro-intestinal diseases

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted